Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Company profile
Ticker
XLRN
Exchange
Website
CEO
Habib Dable
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acceleron Securities Corp. • Acceleron Holding Ltd. • Acceleron Pharma Switzerland AG ...
XLRN stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
2 Dec 21
8-K
Completion of Acquisition or Disposition of Assets
22 Nov 21
25-NSE
Exchange delisting
22 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
22 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
22 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 21
SC TO-T/A
Third party tender offer statement (amended)
17 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
12 Nov 21
SC 14D9/A
Tender offer solicitation (amended)
10 Nov 21
Transcripts
XLRN
Earnings call transcript
2021 Q2
8 Aug 21
XLRN
Earnings call transcript
2021 Q1
9 May 21
XLRN
Earnings call transcript
2020 Q4
26 Feb 21
XLRN
Earnings call transcript
2020 Q3
8 Nov 20
XLRN
Earnings call transcript
2020 Q3
5 Nov 20
XLRN
Earnings call transcript
2020 Q2
8 Aug 20
XLRN
Earnings call transcript
2020 Q1
11 May 20
XLRN
Earnings call transcript
2019 Q4
27 Feb 20
XLRN
Earnings call transcript
2019 Q3
6 Nov 19
XLRN
Earnings call transcript
2019 Q2
5 Aug 19
Latest ownership filings
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 337.85 mm | 337.85 mm | 337.85 mm | 337.85 mm | 337.85 mm | 337.85 mm |
Cash burn (monthly) | (no burn) | 32.79 mm | 23.54 mm | 21.29 mm | 23.63 mm | 21.78 mm |
Cash used (since last report) | n/a | 1.01 bn | 726.60 mm | 657.09 mm | 729.26 mm | 672.18 mm |
Cash remaining | n/a | -674.00 mm | -388.75 mm | -319.23 mm | -391.41 mm | -334.32 mm |
Runway (months of cash) | n/a | -20.6 | -16.5 | -15.0 | -16.6 | -15.4 |
Institutional ownership, Q1 2023
11.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 674.78 mm |
Total shares | 7.01 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BMY Bristol-Myers Squibb | 7.01 mm | $674.78 mm |